A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 13 Feb 2015
Price : $35 *
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy; Insomnia; Partial epilepsies
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 09 Feb 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 16 Dec 2014 Planned End Date changed from 1 May 2016 to 1 Aug 2016, according to the ClinicalTrials.gov record.
- 16 Dec 2014 Planned primary completion date changed from 1 Apr 2016 to 1 Aug 2016, according to the ClinicalTrials.gov record.